Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
January 26, 2021 08:18 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma to Participate in Virtual Conference on Investing in Psychedelics
January 19, 2021 08:13 ET
|
Silo Pharma, Inc.
NEW JERSEY , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research...
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
January 13, 2021 08:45 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
January 11, 2021 08:30 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week...
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
January 06, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin
December 15, 2020 08:30 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today...
Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham
December 07, 2020 08:15 ET
|
Silo Pharma, Inc.
NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
Silo Pharma Comments on Recent Promotional and Trading Activities at Request of OTC Markets
December 04, 2020 16:52 ET
|
Silo Pharma, Inc.
NEW JERSEY , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that...
Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco
November 16, 2020 09:40 ET
|
Silo Pharma, Inc.
NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D....
Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications
November 12, 2020 07:07 ET
|
Silo Pharma, Inc.
Each Provisional Patent Application Relates to Psilocybin NEW YORK , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on...